Translational research made with Cannabis sativa L. and its biocompounds provides data for some targeted diseases, as also symptoms associated with Autism Spectrum Disorders (ASDs). The main compounds ∆9-tetrahydrocannabinol (THC) and cannabidiol (CBD), are capable of modulating the endocannabinoid system since its dysregulation interferes with the pathophysiology of ASDs there are clinical evidence for its potential use in the treatment of the disease. Conventional therapy still has limitations, as it does not always treat the central symptoms, and there are many patients who do not respond to treatment, which demands more research on new therapies. Through the analysis of published literature on this topic, it is verified that cannabinoids, in particular CBD, improves symptoms associated with common comorbidities in ASDs. Some studies also demonstrate the therapeutic potential of these compounds in the treatment of central symptoms of autism. In addition, cannabinoid therapy to ASDs is associated with low adverse effects and a reduction in concomitant medication.
|Diseases and Symptoms||Therapeutic Potential of Cannabinoids|
|Tourette’s Syndrome||Improvement of symptomatology|
|Glaucoma||Intraocular pression reduction|
|Inflammatory Bowel Diseases||Anti-inflammatory
|Sleep Disorders||Decrease sleep latency and nocturnal awakenings
|Post-Traumatic Stress Disorder||Anxiolytic|
|Nausea and Vomiting||Antiemetic|